General Information of the Disease (ID: M6ADIS0091)
Name
Acute ischemic stroke
ICD
ICD-11: 8B11
Full List of Target Gene(s) of This m6A-centered Disease Response
Mutated in multiple advanced cancers 1 (PTEN)
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [3]
Response Summary YTHDC1 promoted Mutated in multiple advanced cancers 1 (PTEN) mRNA degradation to increase Akt phosphorylation, thus facilitating neuronal survival in particular after ischemia, modulating m6A reader YTHDC1 provide a potential therapeutic target for ischemic stroke.
Responsed Disease Acute ischemic stroke [ICD-11: 8B11]
Target Regulator YTH domain-containing protein 1 (YTHDC1) READER
Target Regulation Down regulation
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model Male SD rats weighing 200-250 g were anesthetized using 4% isoflurane in 70% N2O and 30% O2 with a mask. A midline incision was made in the neck, the left external carotid artery (ECA) was carefully exposed and dissected, a monofilament nylon suture with a diameter of about 0.22 mm was inserted from the ECA into the internal carotid artery, and the left middle cerebral artery (MCA) was blocked. After occlusion for 90 minutes, the suture was removed for reperfusion, and ECA was ligated to close the wound. Sham-operated rats underwent the same surgery except for suture insertion. Rats were maintained on top of a warming pad (RWD, 69003) during the above procedures. The breathing machine was used to monitor the respiration of rats. The rats were returned to a heated cage during the recovery phase with free access to food and water.
microRNA 335 (MIR335)
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [15]
Response Summary METTL3-mediated m6A methylation increases the maturation of microRNA 335 (MIR335), which promotes SG formation and reduces the apoptosis level of injury neurons and cells, and provides a potential therapeutic strategy for acute ischemic stroke.
Responsed Disease Acute ischemic stroke [ICD-11: 8B11]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
Target Regulation Up regulation
Cell Process RNA maturation
Cell apoptosis
In-vitro Model PC-12 Lung papillary adenocarcinoma Homo sapiens CVCL_S979
In-vivo Model After a median incision on the neck, the left common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA) were isolated. The left CCA and the ECA were ligated.
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 11 item(s) under this disease
Crosstalk ID: M6ACROT02073
m6A Regulator ELAV-like protein 1 (ELAVL1)
m6A Target DNA (cytosine-5)-methyltransferase 3B (DNMT3B)
Epigenetic Regulator DNA (cytosine-5)-methyltransferase 3B (DNMT3B)
Regulated Target Serine/threonine-protein kinase PINK1, mitochondrial (PINK1)
Crosstalk relationship m6A → DNA modification
Crosstalk ID: M6ACROT03206
m6A Regulator Methyltransferase-like 14 (METTL14)
m6A Target Histone deacetylase 3 (HDAC3)
Epigenetic Regulator Histone deacetylase 3 (HDAC3)
Crosstalk relationship m6A → Histone modification
Crosstalk ID: M6ACROT03207
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
m6A Target Histone deacetylase 3 (HDAC3)
Epigenetic Regulator Histone deacetylase 3 (HDAC3)
Crosstalk relationship m6A → Histone modification
Crosstalk ID: M6ACROT05025
m6A Regulator YTH domain-containing protein 1 (YTHDC1)
m6A Target Ubiquitin-like-conjugating enzyme ATG10 (ATG10)
Epigenetic Regulator Colorectal neoplasia differentially expressed (CRNDE)
Regulated Target YTH N6-methyladenosine RNA binding protein C1 (YTHDC1)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05099
m6A Regulator Fat mass and obesity-associated protein (FTO)
m6A Target Dynamin-1-like protein (DRP1)
Epigenetic Regulator ZNFX1 antisense RNA 1 (ZFAS1)
Regulated Target FTO alpha-ketoglutarate dependent dioxygenase (FTO)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05105
m6A Regulator RNA demethylase ALKBH5 (ALKBH5)
m6A Target H19 imprinted maternally expressed transcript (H19)
Epigenetic Regulator H19 imprinted maternally expressed transcript (H19)
Regulated Target hsa-miR-124-3p
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05263
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Transcription factor p65 (RELA)
Epigenetic Regulator hsa-miR-421-3p
Regulated Target YTH domain-containing family protein 1 (YTHDF1)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05434
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target microRNA 335 (MIR335)
Epigenetic Regulator MicroRNA 335 (MIR335)
Regulated Target ZFP36 ring finger protein like 1 (ZFP36L1)
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05690
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target LINC00035 (ABHD11-AS1)
Epigenetic Regulator LINC00035 (ABHD11-AS1)
Regulated Target hsa-miR-1301-3p
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05727
m6A Regulator Fat mass and obesity-associated protein (FTO)
m6A Target Maternally expressed 3 (MEG3)
Epigenetic Regulator Maternally expressed 3 (MEG3)
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05821
m6A Regulator RNA demethylase ALKBH5 (ALKBH5)
m6A Target Small nucleolar RNA host gene 3 (SNHG3)
Epigenetic Regulator Small nucleolar RNA host gene 3 (SNHG3)
Regulated Target ELAV-like protein 1 (HuR/ELAVL1)
Crosstalk relationship m6A → ncRNA
References
Ref 1 Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72. doi: 10.1021/jm060713d.
Ref 2 Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci. 2008 Sep;108(1):40-8. doi: 10.1254/jphs.fp0072346. Epub 2008 Sep 6.
Ref 3 YTHDC1 mitigates ischemic stroke by promoting Akt phosphorylation through destabilizing PTEN mRNA. Cell Death Dis. 2020 Nov 13;11(11):977. doi: 10.1038/s41419-020-03186-2.
Ref 4 Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41. doi: 10.1080/004982599238632.
Ref 5 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 6 Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007 Jul;133(1):207-18. doi: 10.1053/j.gastro.2007.03.114. Epub 2007 Apr 11.
Ref 7 ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010 Apr 24;86(17-18):631-7.
Ref 8 Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes Obes Metab. 2020 Jan;22(1):30-38. doi: 10.1111/dom.13862. Epub 2019 Oct 1.
Ref 9 Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20. doi: 10.2147/BTT.S57253. eCollection 2014.
Ref 10 Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41. doi: 10.1021/jm500627s. Epub 2014 Jul 9.
Ref 11 ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Ref 12 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801.
Ref 13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
Ref 14 Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. doi: 10.3389/fgene.2015.00325. eCollection 2015.
Ref 15 Methyltransferase 3 Mediated miRNA m6A Methylation Promotes Stress Granule Formation in the Early Stage of Acute Ischemic Stroke. Front Mol Neurosci. 2020 Jun 5;13:103. doi: 10.3389/fnmol.2020.00103. eCollection 2020.
Ref 16 Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509. doi: 10.1310/hpj4806-494.
Ref 17 FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
Ref 18 Company report (Biooncology)
Ref 19 Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48. doi: 10.1016/s0009-2797(00)00304-5.
Ref 20 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem. 2007 Aug 23;50(17):4027-37. doi: 10.1021/jm070077z. Epub 2007 Aug 1.
Ref 21 Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289. doi: 10.1186/s13046-019-1289-6.
Ref 22 Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett. 2004 Sep 10;574(1-3):55-61.
Ref 23 WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer.
Ref 24 Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013 Apr;31(2):370-80. doi: 10.1007/s10637-012-9825-7. Epub 2012 Jun 2.